Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function

Clinical and Experimental Allergy

Volumn 48, Issue 7, 2018, Pages 825-836

  Abdel Gadir, A ^a   Schneider, L ^a   Casini, A ^b   Charbonnier, L M ^a   Little, S V ^a   Harrington, T ^a   Umetsu, D T ^c   Rachid, R ^a   Chatila, T A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c GENENTECH INC   (United States)

Author keywords

food allergy; FOXP3; omalizumab; oral immunotherapy; regulatory T cells

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; OMALIZUMAB; TRANSCRIPTION FACTOR FOXP3; ALLERGEN; ANTIALLERGIC AGENT; BIOLOGICAL MARKER; CYTOKINE;

AGED; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CPG ISLAND; CYTOKINE PRODUCTION; DNA METHYLATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH2 CELL; DESENSITIZATION; DRUG EFFECT; GENETIC EPIGENESIS; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PHENOTYPE;

ADMINISTRATION, ORAL; ALLERGENS; ANTI-ALLERGIC AGENTS; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; OMALIZUMAB; PHENOTYPE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH2 CELLS;

EID: 85047777892     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.13161     Document Type: Article

References (38)

1. Eigenmann PA, Beyer K, Wesley Burks A, et al. New visions for food allergy: an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19(Suppl 19):26-39.
2. Sicherer SH. Food allergy. Mt Sinai J Med. 2011;78:683-696.
3. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291-307; quiz 8.
4. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644-651.
5. Chinthrajah RS, Hernandez JD, Boyd SD, Galli SJ, Nadeau KC. Molecular and cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol. 2016;137:984-997.
6. Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133:468-475.
7. Syed A, Garcia MA, Lyu SC, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133:500-510.
8. Hussey Freeland DM, Fan-Minogue H, Spergel JM, Chatila TA, Nadeau KC. Advances in food allergy oral immunotherapy: toward tolerance. Curr Opin Immunol. 2016;42:119-123.
9. Berin MC, Shreffler WG. Mechanisms underlying induction of tolerance to foods. Immunol Allergy Clin North Am. 2016;36:87-102.
10. Bryce PJ. Balancing tolerance or allergy to food proteins. Trends Immunol. 2016;37:659-667.
11. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292-300, e1-97.
12. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654-660.
13. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4 + CD25 + regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199:1679-1688.
14. Shreffler WG, Wanich N, Moloney M, Nowak-Wegrzyn A, Sampson HA. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. J Allergy Clin Immunol. 2009;123:43-52.e7.
15. Qamar N, Fishbein AB, Erickson KA, et al. Naturally occurring tolerance acquisition to foods in previously allergic children is characterized by antigen specificity and associated with increased subsets of regulatory T cells. Clin Exp Allergy. 2015;45:1663-1672.
16. Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138:801-811.e9.
17. Noval Rivas M, Burton OT, Wise P, et al. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015;42:512-523.
18. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127:1622-1624.
19. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132:1368-1374.
20. MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139:873-881.e8.
21. Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012;5:267-276.
22. Charbonnier LM, Wang S, Georgiev P, Sefik E, Chatila TA. Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat Immunol. 2015;16:1162-1173.
23. Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016;138:639-652.
24. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
25. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013;43:2797-2809.
26. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159:814-828.
27. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14:24-35.
28. Sanchez Rodriguez R, Pauli ML, Neuhaus IM, et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124:1027-1036.
29. Baron U, Floess S, Wieczorek G, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol. 2007;37:2378-2389.
30. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38.
31. Burton OT, Logsdon SL, Zhou JS, et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134:1310-1317.e6.
32. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123-1129.e2.
33. Logsdon SL, Oettgen HC. Anti-IgE therapy: clinical utility and mechanistic insights. Curr Top Microbiol Immunol. 2015;388:39-61.
34. Burton OT, Noval Rivas M, Zhou JS, et al. Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells. Immunity. 2014;41:141-151.
35. Frischmeyer-Guerrerio PA, Masilamani M, Gu W, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043-1053.e8.
36. Ryan JF, Hovde R, Glanville J, et al. Successful immunotherapy induces previously unidentified allergen-specific CD4 + T-cell subsets. Proc Natl Acad Sci U S A. 2016;113:E1286-E1295.
37. Berin MC, Mayer L. Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol. 2013;131:14-22.
38. Santos AF, James LK, Bahnson HT, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 2015;135:1249-1256.